Biocon Limited announced its audited financial results for the quarter and year ended March 31, 2026. The board approved a final dividend of Re. 0.50 per share and outlined a strategic plan to fully integrate its material subsidiary, Biocon Biologics Limited (BBL), into a unified global biopharmaceutical entity. The company also announced key leadership changes and the appointment of new statutory auditors to support its next growth phase.
Financial Highlights
For the financial year ended March 31, 2026, Biocon reported consolidated total income of Rs. 1,72,695 million, compared to Rs. 1,64,699 million in the previous year. The consolidated net profit for the year stood at Rs. 3,688 million. The company has recommended a final dividend of 10%, amounting to Re. 0.50 per equity share of Rs. 5 face value, which is subject to shareholder approval at the upcoming Annual General Meeting on August 06, 2026. The record date for this dividend is fixed for July 03, 2026.
Strategic Integration of Biocon Biologics
In a move to create a Unified Global Biopharmaceutical Leader, Biocon has initiated the full integration of Biocon Biologics Limited (BBL). The board approved the acquisition of the remaining stake in BBL held by minority shareholders through a share swap arrangement, issuing up to 87,92,317 equity shares of Biocon. This consolidation is designed to simplify the corporate structure, optimize capital allocation, and capture operational synergies across the Biosimilars and GLP-1 portfolios.
Leadership and Governance Updates
The company announced significant leadership appointments, including Dr. Anuj Goel as Chief Development Officer and Mr. Susheel Umesh as Chief Commercial Officer for Emerging Markets, who are now designated as Senior Management Personnel. Furthermore, the board recommended the appointment of M/s. S. R. Batliboi & Associates LLP as the new statutory auditors for a five-year term starting from the conclusion of the 48th AGM, succeeding M/s. B S R & Co. LLP.
New Director Appointments
To support the company’s next phase of global expansion, the board has recommended several high-profile appointments to its leadership team effective August 01, 2026, including Mr. Rajiv Malik, Mr. Daniel Bradbury, Mr. Peter Baron Piot, Mr. Arun Suresh Chandavarkar, and Ms. Nivruti Rai as Independent Directors, alongside Mr. Thomas Jason Roberts as a Non-Executive Non-Independent Director.
Source: BSE
